We are live on ! Find out more
AKRO

Akero Therapeutics
AKRO

Delisted

AKRO was delisted on the 8th of December, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of AKRO yet.

AKRO Hedge Fund Activity: Q1 2026 in Review

0 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2026, worth a combined $0 — down 100% from $533K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of AKRO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $532K sold.

  • 0 institutional investors held Akero Therapeutics (AKRO) as of Q1 2026, down from 2 in Q4 2025.
  • Funds reported $0 of Akero Therapeutics stock for Q1 2026, down 100% quarter-over-quarter.
  • 0 funds opened new Akero Therapeutics positions in Q1 2026 and 2 closed out, a net change of -2 holders.
  • The largest Akero Therapeutics seller in Q1 2026 was DekaBank Deutsche Girozentrale, an estimated $532K sold.

Based on aggregated 13F filings for Q1 2026.